VRTX Vertex Pharmaceuticals

Q3 2025 10-Q

Filed: Nov 4, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Vertex Pharmaceuticals (VRTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $3.1B in Q3 2025, up 11% from $2.8B in Q3 2024, driven by TRIKAFTA/KAFTRIO and new launches including ALYFTREK and JOURNAVX
• Operating margin improved: income from operations $1.19B (39% margin) in Q3 2025 vs $1.12B (40% margin) in Q3 2024, cost of sales down to 13.5% from 14.2%

+3 more insights

Risk Factors

• No newly added risk factors this quarter; no material changes from 2024 10-K risk disclosures
• Carryforward regulatory risk: challenges obtaining accelerated approvals and maintaining reimbursement coverage

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.1B

Net Income

$1.1B

Net Margin

35.2%

Source: XBRL data from Vertex Pharmaceuticals Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Vertex Pharmaceuticals Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Vertex Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.